Functional Medical Imaging Quantization in Prostate Cancer

Prostate Cancer Clinical Trial

— QUIP  

Official title:

Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer: Preliminary Results Concerning the Length of the Acquisition

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03376360
• Other study ID #: QUIP
• Status: Completed
• Start date: October 1, 2015
• Est. completion date: May 1, 2017

Study information

• Verified date: November 2017
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Prostate cancer is the most common cancer in men over 50 years old and the third leading cause of cancer death. Because of the variety of prostate cancers, different treatments exist.

Several criteria guide this management in daily practice: PSA level; TNM stage (digital rectal examination, trans-rectal ultrasound and classical visual imaging) and pathological differentiation with the Gleason score, to which can be added other prognostic criteria: growth and doubling time of the serum PSA, number of positive biopsies and percentage of cancer lesions by biopsy.

Functional imaging by PET and MRI is increasingly used in daily clinical practice to characterize prostate cancer, either during initial discovery or during recurrence. In this context, it is the qualitative visual analysis that is mainly used. Quantitative image analysis could add new criteria to guide patient management.

Consequently, the objective of this study were:

• Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer

• Comparison the quantitative parameters obtained by 18F-Choline PET / CT and both perfusion MRI and histological parameters.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: May 1, 2017
• Est. primary completion date: May 1, 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients with prostate cancer histologically proven included in Brest University Hospital between 01/07/2012 and 01/10/2015 and underwent F-choline PET/CT and pelvic MRI Patient consent

Exclusion Criteria:

No lesion on dynamic acquisition on PET/CT and/or on pelvic MRI

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Locations

Country	Name	City	State
France	CHRU de Brest	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	correlation between Gleason score and dynamic parameters on PET and MRI	study the potential correlation between dynamic parameters on PET and MRI	when anatomopathological report is available, an average of 3 months after the PET/CT
Secondary	reconstructions on 18F-choline PET	determine the mean influx from each reconstruction which is the closest to the objective value	when all 18F-choline PET are performed, an average of 6 months
Secondary	best "fitting" on PET and MRI	the Akaike Criteria Information was chose to choose the best fit	when all MRI are performed, an average of 6 months
Secondary	comparison between data (PSA, TNM stage, EFS and OS)	comparison between data (PSA, TNM stage, EFS and OS)	01/05/2017